Tenpoint Therapeutics won U.S. FDA approval for Yuvezzi, a combination eye drop for adult presbyopia, and announced financing to support commercialization. The FDA clearance makes Yuvezzi the first dual‑agent topical treatment combining carbachol and brimonidine tartrate, positioning Tenpoint in a crowded presbyopia market alongside single‑agent competitors. The company simultaneously closed a $235 million financing package—including equity and a $150 million senior secured loan—to fund launch activities and commercial scale‑up.